Alexion Pays Hefty $8.4 Billion To Acquire Synageva, Expand Rare Disease Drug Business

CHESHIRE, Conn. (TheStreet) -- Alexion Pharmaceuticals is buying Synageva Biopharma for $8.4 billion to broaden its offering of treatments for rare diseases, the companies announced Wednesday. The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days. That's a 140% premium to Synageva's closing price of $95.87 on Tuesday. Alexion is already one of the most successful marketers of so-called "ultra orphan drugs" -- treatments for rare, genetic diseases which carry gigantic price tags.

BING NEWS:
  • Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
    Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development ...
    04/21/2024 - 6:49 pm | View Link
  • Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease
    She adds that working in rare disease is unique in that there is an “overwhelming need” to be agile and flexible. “There’s a lot that drug development for more common diseases could learn ...
    02/4/2023 - 9:39 pm | View Link
  • Alexion expands its reach in ultra-rare disease
    New therapies will help Alexion rapidly expand over the next few years ... predicament demonstrates that developing an ultra-rare disease drug is not a licence to print money.
    09/21/2015 - 1:00 pm | View Link
  • Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition
    Shares of Synageva Biopharma (GEVA) more than doubled to a 52-week high of $215.74 on Wednesday after Alexion Pharmaceuticals ALXN agreed to acquire it for $8.4 billion. Shares of Synageva ...
    05/6/2015 - 6:59 am | View Link
  • Alexion Pharmaceuticals (ALXN) Stock Falls After Agreeing to Acquire Synageva Biopharma
    Shares of Alexion Pharmaceuticals (ALXN) were down in afternoon trading Wednesday after the company agreed to acquire Synageva Biopharma for $8.4 billion ... to treat two rare disorders: atypical ...
    05/6/2015 - 6:38 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News